Rheumatology News

COVID-19 does not increase patients’ risk for developing myalgic encephalomyelitis/chronic fatigue syndrome during the 1-year period post infection, according to a registry study published in JAMA Network Open.

The FDA has granted fast track designation to CB-010, an allogeneic anti-CD19 CAR T-cell therapy from Caribou Biosciences, for refractory systemic lupus erythematosus ahead of a planned phase 1 trial, according to a press release.

Nearly all biologic and targeted synthetic disease-modifying antirheumatic drugs come with infection or malignancy warnings from U.S. or European regulatory agencies, according to a study published in Drug Safety.

The use of machine learning models to predict treatment response in rheumatoid arthritis is increasing, though approximately 80% show “unclear and high risk of bias,” according to data published in Seminars in Arthritis and Rheumatism.

Attempts to curtail prior authorizations for patients insured by Medicare Advantage plans have failed in back-to-back legislative sessions in 2019 and 2021, but a new bill has some experts hopeful that the third time is a charm.

The FDA has approved an updated label for Gloperba, an oral liquid colchicine formulation, allowing for precision dosing, according to a press release from Scilex Holding Company.

Systemic immune-inflammation index levels may be used to predict all-cause and cardiovascular mortality among patients with rheumatoid arthritis, according to data published in Scientific Reports.

Patients who received an mRNA COVID-19 vaccine demonstrated a 1.16-fold higher long-term risk for systemic lupus erythematosus, while a booster was linked to higher risk for psoriasis and rheumatoid arthritis, according to data.

Women who consume the greatest daily amount of ultraprocessed foods on average demonstrate a 56% higher risk for systemic lupus erythematosus, according to data published in Arthritis Care & Research.